
An experimental Alzheimer’s disease drug that appears to slow down cognitive decline has been given fast-track approval by the US Food and Drug Administration.
The approval on Friday comes after clinical trial results published last November indicated that the drug, lecanemab, successfully slows cognitive decline in people with mild impairment from the disease.